Drug discovery has quickly become the most enticing place to apply artificial intelligence. Billions of dollars are being invested in AI-driven “techbios.” In an industry where nothing changes overnight, even large biopharma companies are touting AI as key to how they’re transforming their discovery engines.
But in the race to integrate AI into drug discovery, investing so heavily in scaling one part of the system overlooks the rest. Failing to reimagine R&D systems to handle the new speed and scale of AI-driven discovery risks overpromising and under-delivering to the people who need new medicines.
Click this link for the original source of this article.
Author: Ashu Singhal and Sajith Wickramasekara
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.